Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Eli Lilly makes transparency vow
With all the talk about big pharma paying physicians for this or that, Eli Lilly is taking on the role of industry forerunner. In a proactive move, the pharma giant says it will start to become transparent about just how much cash it doles out to physicians and for what purpose.
Perhaps with more and more members of Congress setting a disclosure bill in motion, Lilly decided to come face to face with what might be inevitable. Regardless of what happens, it's a decent PR move and pharma companies definitely need good PR these days.
Specifically, Lilly will disclose how much it pays individual physicals for advisory roles, speeches and other services, as long as the payments are more than $500. The listing will be on a public database. However, Lilly will not be disclosing payments to physicians for travel, gifts and entertainment at this time.
- here's Lilly's release
- read the Associated Press story
Related Articles:
Arms twisted, pharma promises disclosure
Doc disclosure gets boost from AZ, Merck
Pharma racks up multibillion-dollar marketing bill
Senate investigates pharma influence on CME
Comments
Too little, too late.
In addition, Lilly needs to be transparent about its research, including the pharmacological and physiological research. It should also include the clinical work that was deep sixed. If it had, there would have fewer problems with Prozac and Byetta.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


